Week in Review: Boehringer Signs $730 Million Deal for Hanmi SCLC Drug

Boehringer Ingelheim will pay Korea's Hanmi Pharma up to $730 million for global rights to a novel lung cancer drug; ZAI Lab in-licensed global rights to an innovative Sanofi multi-kinase inhibitor aimed at non-small cell lung cancer; Jiangsu Hengrui in-licensed China rights to an anti-nausea/vomiting drug from Tesaro of the US; Hutchison Chi-Med restructured Mitsui's 12.2% interest in its drug development subsidiary into a 5.7% interest (worth $84 million) in the Chi-Med parent company; Bloomage BioTechnology formed a China JV with South Korea's Medytox to market Medytox's version of the cosmetic drug Botox; Shuwen Biotech, a Hangzhou diagnostic company, will collaborate with Jiangsu Hengrui to develop a companion cancer diagnostic; the CFDA will hold drugmakers responsible for the accuracy of their clinical trial data, threatening penalties of up to a three-year prohibition of any new drug filings; Suzhou Connect reported positive data from a Phase I study of CBP-307, a drug candidate for several autoimmune diseases; Jun Wang, the CEO of BGI, China's major genomic sequencing company, is relinquishing his CEO title; and Yabao Pharma began preclinical work on an innovative drug candidate for sepsis based on annexin A5. More details.... Stock Symbols: (NYSE: SNY) (SHA: 600276) (NSDQ: TSRO) (AIM: HCM) (HK: 00963) (KS: 086900) (SHA: 600276) (SHA: 600351) Share this with colleagues: // //